LG Chem’s Aveo Sues Hetero to Block Copies of Kidney-Cancer Drug

LG Chem Ltd.’s Aveo Pharmaceuticals Inc. sued Hetero Labs Ltd. to block proposed copies of Aveo’s kidney-cancer drug Fotivda that it said infringe a patent covering dosing methods for patients with liver impairment.

Hetero’s generic 0.89- and 1.34-milligram tablets of tivozanib hydrochloride—Fotivda’s active ingredient—infringe Aveo’s US Patent No. 11,504,365, according to a complaint filed Friday in the US District Court for the District of Delaware.

• The patent expires in November 2039—the latest of the three patents listed for Fotivda in the US Food and Drug Administration’s registry of approved drugs, the Orange Book. It covers a way to treat ...